Menu
Enrolling by invitation NCT03393962

Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors

Phase I / Phase II Interventional Ovarian Cancer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: OC-EIEs.
Who it may be relevant to
Registry conditions: Ovarian Cancer. Basic parameters: 10 years — 80 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Interventional Treatment of Ovarian Cancer With Cancer Antigen-specific Engineered Immune Effector T Lymphocytes (OC-EIEs)

Overview

This is a single-arm, open-label, phase I/II trial to evaluate the safety and efficacy of ovarian cancer-specific, engineered immune effectors (OC-EIEs) in women.

Detailed description

Ovarian cancer (OC) is a cancer that is derived from an ovary. The majority of OC arises from the epithelium (outer lining) of the ovary. In 2015, OC was found in 1.2 million women and resulted in 161,100 deaths worldwide. Among women, OC is the seventh-most common cancer and the eighth-most common cause of cancer death. Treatment for OC consists of surgery, chemotherapy, immunotherapy and radiotherapy. The kind of treatment depends on many factors, including the type of OC, its stage and grade, as well as the general health of the patient.

Adoptive immunotherapy with cytotoxic T lymphocytes (CTLs) reactive with tumor antigens has proven to be effective against many types of cancer. OC has been shown to be highly immunogenic and therefore may respond well to innovative antigen-specific immunotherapy. Here, through cancer antigen screening and careful target antigen evaluation, the investigation aims to evaluate the safety and efficacy of multiple infusions of OC antigen-specific, engineered immune effectors (EIEs) in patients with OC.

Interventions

  • Biological OC-EIEs
    2 to 4 infusions, once a week, 0.1\~4x10\^6 CTLs/kg; injection via IV, abdominal cavity or intrastumoral.

Primary outcome measures

  • Safety of OC-EIEs in patients using CTCAE version 4.0 standard to evaluate the level of adverse events [Time frame: 6 months]
Secondary outcome measures (5)
  • Expansion of OC-EIEs [Time frame: 8 weeks.]
  • percentage of complete response [Time frame: 1 year]
  • percentage of partial response [Time frame: 1 year]
  • percentage of stable disease [Time frame: 1 year]
  • percentage of progressive disease [Time frame: 1 year]

Eligibility criteria

Inclusion criteria

  • Written, informed consent obtained prior to any study-specific procedures.
  • Age older than 10 years.
  • Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1.
  • Expected survival ≥ 12 weeks.
  • Histologically confirmed and documented high risk International Federation of Gynecology and Obstetrics (FIGO): Stage II-IV.
  • Not pregnant, and on appropriate birth control of childbearing potential.
  • Initial hematopoietic reconstitution with
  • neutrophils (ANC) ≥ 1,000/mm\^3;
  • platelet (PLT) ≥ 100,000/mm\^3.
  • Proper renal and hepatic functions (ULN denotes "upper limit of normal range") with
  • serum creatinine ≤ 2×ULN;
  • serum bilirubin ≤ 2×ULN;
  • AST/ALT ≤ 2×ULN;
  • ALKP ≤ 5×ULN;
  • serum bilirubin. 2.0 is acceptable in the setting of known Gilbert's syndrome.
  • Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) test negative.

Exclusion criteria

  • Patients with ovarian tumors with low malignant potential (i.e. borderline tumors);
  • Patients with evidence of abdominal free air not explained by paracentesis or recent surgical procedure (prior, current or planned treatment).
  • Prior treatment of any adoptive T cell therapy.
  • Current or recent treatment (within the 14-day period prior to Day 0) with any immune suppressive drug
  • Minor surgical procedures within 2 days prior to Day 0 (including central venous access device placement for chemotherapy administration, tumor biopsies, needle aspirations).
  • Pregnant or lactating females.
  • Inadequate bone marrow function with
  • absolute neutrophil count < 1,000/mm\^3;
  • platelet count < 100,000/mm\^3;
  • Hb < 9 g/dL.
  • Inadequate liver and renal function with
  • serum (total) bilirubin > 1.5 x ULN;
  • AST \& ALT > 2.5 x ULN (> 5 x ULN in patients with liver metastases);
  • alkaline phosphatase > 2.5 x ULN;
  • serum creatinine >2.0 mg/dl (> 177 μmol/L);
  • urine dipstick for protein uria should be < 2+. Patients with ≥ 2+ proteinuria on dipstick urinalysis at baseline should undergo 24 hour urine collection and must demonstrate < 1 g of protein/24 hr.
  • Serious active infection requiring i.v. antibiotics
  • Subject infected with HCV (HCV antibody positive), or HIV (HIV antibody positive),Treponema pallidum antibody positive or TB culture positive.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

China · 1 center
  • Shenzhen Geno-immune Medical Institute — Shenzhen

Identifiers

NCT: NCT03393962 · GIMI-IRB-17024

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗